MNOV vs. FENC, VOR, EDIT, DBVT, IMMP, ANNX, VYGR, LYEL, TKNO, and TNXP
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Adherex Technologies (FENC), Vor Biopharma (VOR), Editas Medicine (EDIT), DBV Technologies (DBVT), Prima BioMed (IMMP), Annexon (ANNX), Voyager Therapeutics (VYGR), Lyell Immunopharma (LYEL), Alpha Teknova (TKNO), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.
MediciNova vs. Its Competitors
Adherex Technologies (NASDAQ:FENC) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.
Adherex Technologies presently has a consensus price target of $13.33, suggesting a potential upside of 53.79%. MediciNova has a consensus price target of $7.00, suggesting a potential upside of 464.52%. Given MediciNova's higher possible upside, analysts clearly believe MediciNova is more favorable than Adherex Technologies.
MediciNova has a net margin of 0.00% compared to Adherex Technologies' net margin of -35.05%. Adherex Technologies' return on equity of 0.00% beat MediciNova's return on equity.
In the previous week, MediciNova had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 4 mentions for MediciNova and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.62 beat MediciNova's score of 0.98 indicating that Adherex Technologies is being referred to more favorably in the media.
Adherex Technologies has higher revenue and earnings than MediciNova. Adherex Technologies is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.
55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 11.0% of Adherex Technologies shares are held by company insiders. Comparatively, 13.6% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Adherex Technologies has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
Summary
MediciNova beats Adherex Technologies on 8 of the 15 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
This page (NASDAQ:MNOV) was last updated on 9/15/2025 by MarketBeat.com Staff
